The Technical Analyst
Mustang Bio Inc [MBIO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Mustang Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-11.58% $0.316
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.28 mill |
| EPS: | -6.00 |
| P/E: | -0.0500 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 10.39 mill |
| Avg Daily Volume: | 0.213 mill |
| RATING 2024-04-26 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0500 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0500 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.434 (37.37%) $0.118 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.191 - 0.441 ( +/- 39.54%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-19 | Murphy James B | Buy | 0 | |
| 2024-01-02 | Fortress Biotech, Inc. | Buy | 419 092 | COMMON STOCK, PAR VALUE $0.0001 |
| 2023-12-11 | Carney Peter | Sell | 0 | Common Stock |
| 2023-07-05 | Zelefsky Michael J | Buy | 7 246 | COMMON STOCK, PAR VALUE $0.0001 |
| 2023-07-05 | Chill Adam J. | Buy | 7 246 | COMMON STOCK, PAR VALUE $0.0001 |
| INSIDER POWER |
|---|
| 100.00 |
| Last 97 transactions |
| Buy: 5 442 388 | Sell: 2 083 593 |
Forecast:
16:00 - $0.316
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.316
Forecast 2: 16:00 - $0.316
Forecast 3: 16:00 - $0.316
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.316 (-11.58% ) |
| Volume | 0.253 mill |
| Avg. Vol. | 0.213 mill |
| % of Avg. Vol | 118.85 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MBIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Latest Press Releases
2024-03-28 09:00:00 - Press Release
Mustang Bio Announces Vision For Car T-cell Therapy Platform Expansion Into Autoimmune Diseases
Planning for proof-of concept phase 1 investigator-sponsored clinical trial evaluating mb-106 cd20-targeted car t-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024
2024-03-11 16:05:00 - Press Release
Mustang Bio Reports Full-year 2023 Financial Results And Recent Corporate Highlights
Worcester, mass., march 11, 2024 (globe newswire) -- mustang bio, inc. (“mustang” or the “company”) (nasdaq: mbio), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended december 31, 2023.
2024-03-07 07:30:00 - Press Release
Mustang Bio Announces Publication In Nature Medicine Of Data From Phase 1 Trial Evaluating Mb-101 Il13rΑ2-targeted Car T-cells In High-grade Glioma
Mb-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively
2024-01-11 08:30:00 - Press Release
Mustang Bio To Participate In The B. Riley Securities 4th Annual Oncology Conference
Worcester, mass., jan. 11, 2024 (globe newswire) -- mustang bio, inc. (“mustang” or the “company”) (nasdaq: mbio), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that manuel litchman, m.d., president and chief executive officer, will participate in a fireside chat at the b. riley securities 4th annual oncology conference, taking place on thursday, january 18, 2024, at 4:30 p.m. est.
2023-12-11 08:30:00 - Press Release
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data For Mb-106 At The 2023 American Society Of Hematology (ash) Annual Meeting
Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent b-cell non-hodgkin lymphoma
Latest News
2023-09-07 08:15:00 - GlobeNewsWire
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.
2023-08-03 08:00:00 - GlobeNewsWire
Mustang Bio to Participate in Two August 2023 Investor Conferences
WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two investor conferences in August 2023.
2023-06-13 15:04:05 - Zacks Investment Research
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.
2023-06-12 10:58:10 - Zacks Investment Research
Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet
The consensus price target hints at a 331.2% upside potential for Mustang Bio, Inc. (MBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2023-05-26 11:05:11 - Zacks Investment Research
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
The mean of analysts' price targets for Mustang Bio, Inc. (MBIO) points to a 711.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2022-09-23 16:55:13 - Seeking Alpha
Mustang Bio: This Horse May Gallop Still
We are circling back on small CAR-T developmental firm Mustang Bio, Inc. today for the first time in nearly a year and a half. The stock has been under pressure since we last looked in on this story, and the shares currently trade for less than net cash on the company's balance sheet.
2022-09-08 08:00:00 - GlobeNewsWire
Mustang Bio to Participate in Upcoming September 2022 Investor Conferences
WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.
2022-06-23 07:00:00 - PennyStocks
What to Know About Buying Penny Stocks on June 23rd
Here's what you need to know about trading penny stocks on June 23rd The post What to Know About Buying Penny Stocks on June 23rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-19 15:28:03 - Benzinga
Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency
Mustang Bio Inc (NASDAQ: MBIO) announced interim data from the Phase 1/2 trial of MB-107, lentiviral gene therapy for X-linked severe combined immunodeficiency (X-SCID), also known as bubble boy disease, in newly diagnosed infants under the age of two. X-SCID is characterized by the.
2022-05-17 15:07:08 - GuruFocus
Caribou Charges Ahead on Study Results
Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the presentations the companies will be making at next month's European Hematology Association meeting.